CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06677710
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:51.953304+00:00
Published At: 2025-04-30T00:00:00+00:00
Record Updated At: 2025-04-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Sclerosis", "Primary Progressive Multiple Sclerosis (PPMS)", "Secondary Progressive Multiple Sclerosis (SPMS)", "Non-Active Secondary Progressive Multiple Sclerosis", "Non-Active SPMS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Autoimmune Diseases", "Demyelinating Diseases", "Immune System Diseases", "Demyelinating Autoimmune Diseases, Central Nervous System (CNS)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-30"
protocolSection.identificationModule.nctId: "NCT06677710"
protocolSection.identificationModule.officialTitle: "A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis"
protocolSection.statusModule.overallStatus: "SUSPENDED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.